Endothelial cell (EC) barrier dysfunction (i.e., increased vascular permeability) is observed in inflammatory states, tumor angiogenesis, atherosclerosis, and both sepsis and acute lung injury. Therefore, agents that preserve vascular integrity have important clinical therapeutic implications. We examined the effects of methylnaltrexone (MNTX), a mu opioid receptor (mOP-R) antagonist, on human pulmonary EC barrier disruption produced by edemagenic agents including morphine, the endogenous mOP-R agonist DAMGO, thrombin, and LPS. Pretreatment of EC with MNTX (0.1 M, 1 h) or the uncharged mOP-R antagonist naloxone attenuated morphine-and DAMGO-induced barrier disruption in vitro. However, MNTX, but not naloxone, pretreatment of EC inhibited thrombinand LPS-induced barrier disruption, indicating potential mOP-Rindependent effects of MNTX. In addition, intravenously delivered MNTX attenuated LPS-induced vascular hyperpermeability in the murine lung. We next examined the mechanistic basis for this MNTX barrier protection and observed that silencing of mOP-R attenuated the morphine-and DAMGO-induced EC barrier disruption, but not the permeability response to either thrombin or LPS. Because activation of the sphingosine 1-phosphate receptor, S1P 3 , is key to a number of barrier-disruptive responses, we examined the role of this receptor in the permeability response to mOP-R ligation. Morphine, DAMGO, thrombin, and LPS induced RhoA/ROCK-mediated threonine phosphorylation of S1P 3 , which was blocked by MNTX, suggesting S1P 3 transactivation. In addition, silencing of S1P 3 receptor expression (siRNA) abolished the permeability response to each edemagenic agonist. These results indicate that MNTX provides barrier protection against edemagenic agonists via inhibition of S1P 3 receptor activation and represents a potentially useful therapeutic agent for syndromes of increased vascular permeability. Keywords: methylnaltrexone; mu opioid receptor; S1P3 receptor; EC barrier regulation; vascular permeability Endothelial cells (EC) provide a semi-selective cellular barrier between the blood and underlying vasculature (1), with disruption of this barrier resulting in increased vascular permeability and organ dysfunction (2-4). Agents that enhance EC barrier function are a desirable therapeutic strategy for a variety of inflammatory diseases, tumor angiogenesis, atherosclerosis, and acute lung injury (5). Methylnaltrexone (MNTX) is a charged, peripherally restricted mu opioid receptor (mOP-R) antagonist currently in development for opiate-induced constipation in advanced illness and in Phase III clinical trials for postoperative ileus (6-9). The mOP-R is expressed in a variety of cell types,
including EC (10) (11) (12) . However, the effects of mOP-R agonists and MNTX on EC barrier regulation are unknown but were examined in this study.
Opioids such as morphine and DAMGO exert their action by binding to the mOP-R present in the central nervous system (CNS) and peripheral tissues (13) (14) (15) . The mOP-R is a G proteincoupled receptor with multiple isoforms resulting from alternative splicing of mRNA encoded from a single gene (13) (14) (15) (16) (17) . Most mOP-R antagonists, including naloxone, exist in an uncharged state and readily pass through the blood-brain barrier (BBB) to exert CNS-dependent analgesic effects (18, 19) . MNTX, however, is a charged molecule that cannot penetrate the BBB (7, 8) , making MNTX a desirable tool by which to examine the effect of opiates and the mOP-R on EC function in the non-CNS peripheral circulations.
Several receptors have been implicated in EC barrier regulation (2) (3) (4) . One important receptor family is the sphingosine-1-phosphate (S1P) receptors (also called endothelial differentiation gene [Edg] receptors). S1P binds to the plasma membrane G protein-coupled S1P receptors 1 (Edg1), 2 (Edg5), 3 (Edg3), 4 (Edg6), and 5 (Edg8) expressed in a variety of cell types including endothelium (5, (20) (21) (22) (23) (24) . Human EC exhibit high expression of S1P 1 and S1P 3 with S1P 1 signaling coupled to the G i pathway and Rac1 activation, whereas S1P 3 signaling couples to the G i , G q/11 , and G 12/13 pathways and activates RhoA to a much greater extent than Rac1 (5, (20) (21) (22) (23) (24) (25) (26) . Activated RhoA can bind to and activate the serine/threonine kinase, ROCK (27, 28) , which is involved in EC barrier disruption (29, 30) . We have previously shown that S1P 1 receptor-dependent activation of Rac1 promotes vascular integrity (2, 3, 22, 29) . In contrast, we have shown that the S1P 3 receptor can potentially regulate EC barrier disruption (29, 31) .
In this study, we demonstrate that methylnaltrexone (MNTX) inhibits opiate-, thrombin-, and LPS-induced EC barrier disruption via transactivation (RhoA/ROCK-mediated threonine phosphorylation) of the S1P 3 receptor. Further, MNTX inhibited LPS-induced pulmonary vascular hyperpermeability in vivo, results suggesting that MNTX may be useful as a potential EC barrier-protective agent.
MATERIALS AND METHODS

Cell Culture and Reagents
Human pulmonary microvascular EC were obtained from Cambrex (Walkersville, MD) and cultured as previously described (2) in EBM-2 complete medium (Cambrex) at 37ЊC in a humidified atmosphere of 5% CO 2 , 95% air, with passages 6-10 used for experimentation. Unless otherwise specified, reagents were obtained from Sigma (St. Louis, MO). Morphine sulfate was purchased from Baxter (Deerfield, IL). Reagents for SDS-PAGE electrophoresis were purchased from BioRad (Richmond, CA), Immobilon-P transfer membrane from Millipore (Millipore Corp., Bedford, MA), and gold microelectrodes from Applied Biophysics (Troy, NY). Rabbit anti-mOP-R antibody was purchased from Abcam (Cambridge, MA). Rabbit anti-S1P 1 receptor antibody was purchased from Affinity Bioreagents (Golden, CO). Mouse anti-S1P 3 receptor antibody was purchased from Exalpha Biologicals (Watertown, MA). Rabbit anti-phospho-serine and rabbit antiphospho-threonine antibodies were purchased from Zymed Laboratories, Inc. (South San Francisco, CA). Rabbit anti-ROCK1, rabbit anti-ROCK2, and rabbit anti-p115 rhoGEF were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse anti-RhoA antibody was purchased from Upstate Biotechnology (Lake Placid, NY). Rabbit antivWF (Factor VIII) antibody was purchased from Chemicon (Temecula, CA). Mouse anti-␤-actin antibody, naloxone, DAMGO, thrombin, LPS, and ionomycin were purchased from Sigma. Secondary horseradish peroxidase (HRP)-labeled antibodies were purchased from Amersham Biosciences (Piscataway, NJ).
Immunoprecipitation and Immunoblotting
Cellular materials from treated or untreated human pulmonary microvascular EC (HPMVEC) were incubated with IP buffer (50 mM HEPES Figure 1 . Characterization of MNTX and opiate effects on human EC barrier regulation. (A ) HPMVEC were seeded on gold microelectrodes, serum starved for 1 h and either left untreated (control) or incubated with 0.1 M methylnaltrexone (MNTX) for 1 h before the addition of morphine sulfate (0.01, 0.1, and 1 M). The TER tracing represents pooled data Ϯ SE from three independent experiments as described in MATERIALS AND METHODS. (B ) HPMVEC were plated on gold microelectrodes, serum starved for 1 h, and either untreated (control) or treated with 0.1 M MNTX for 1 h before the addition of DAMGO (0.01, 0.1, and 1 M). The TER tracing represents pooled data Ϯ SE from three independent experiments as described in MATERIALS AND METH-ODS. (C ) Bar graph demonstrates the effects of increasing concentrations of MNTX on morphine sulfate-and DAMGO-mediated (0.1 M) EC barrier regulation. The bar graph represents the percent maximal TER response (y axis) with morphine sulfate and DAMGO challenge (at least n ϭ 3 for each condition).
[pH 7.5], 150 mM NaCl, 20 mM MgCl 2 , 1% Nonidet P-40 , 0.4 mM Na 3 VO 4 , 40 mM NaF, 50 M okadaic acid, 0.2 mM phenylmethylsulfonyl fluoride, 1:250 dilution of Calbiochem protease inhibitor mixture 3). The samples were then immunoprecipitated with anti-S1P 3 receptor IgG followed by SDS-PAGE in 4-15% polyacrylamide gels, transfer onto Immobilon membranes, and developed with specific primary and secondary antibodies. Visualization of immunoreactive bands was achieved using enhanced chemiluminescence (Amersham Biosciences).
Construction and Transfection of siRNA against mOP-R, S1P 1 receptor, S1P 3 receptor, RhoA, ROCK1, and ROCK2
The siRNA sequence(s) targeting human mOP-R, S1P 1 receptor, and S1P 3 receptor were generated using mRNA sequences from Gen-Bank (gi:56549104, gi:87196352, gi:38788192, gi:33876092, gi:4885582, and gi:41872582, respectively). For each mRNA (or scramble), two targets were identified. Specifically, mOP-R target sequence 1 (5Ј-AACGC CAGCAATTGCACTGAT-3Ј), mOP-R target sequence 2 (5Ј-AATG TCAGATGCTCAGCTCGG-3Ј), S1P 1 target sequence 1 (5Ј-AAGC TACACAAAAAGCCTGGA-3Ј), S1P 1 target sequence 2 (5Ј-AAAAAGCCTGGATCACTCATC-3Ј), S1P 3 target sequence 1 (5Ј-AACAGGGACTCAGGGACCAGA-3Ј), S1P 3 target sequence 2 (5Ј-AAATGAATGTTCCTGGGGCGC-3Ј), RhoA1 target sequence 1 (5Ј-AAAACTTGCCTACTGATCAGT-3Ј), RhoA1 target sequence 2 (5Ј-AACTTGCCTACTGATCAGTTA-3Ј), ROCK1 target sequence 1 Figure 2 . Characterization of MNTX effects on non-opiate agonist-induced human EC barrier regulation. (A ) HPMVEC were seeded on gold microelectrodes, serum starved for 1 h, and either left untreated (control) or incubated with 0.1 M MNTX for 1 h before the addition of thrombin (1 U/ml). The TER tracing represents pooled data Ϯ SE from three independent experiments as described in MATERIALS AND METHODS. (B ) HPMVEC were seeded on gold microelectrodes, serum starved for 1 h, and either left untreated (control) or incubated with 0.1 M MNTX for 1 h before the addition of LPS (1 g/ml). The TER tracing represents pooled data Ϯ SE from three independent experiments as described in MATERIALS AND METHODS. (C ) HPMVEC were seeded on gold microelectrodes, serum starved for 1 h, and either left untreated (control) or incubated with 0.1 M MNTX for 1 h before the addition of S1P (1 M). The TER tracing represents pooled data Ϯ SE from three independent experiments as described in MATERIALS AND (5Ј-AAAAAATGGACAACCTGCTGC-3Ј), ROCK1 target sequence 2 (5Ј-AAGTGAATTCGGATTGTTTGC-3Ј), ROCK2 target sequence 1 (5Ј-AATCTGACTGAGGGGCGGGGA-3Ј), ROCK2 target sequence 2 (5Ј-AAGCCGGAGCTAGAGGCAGGC-3Ј), scrambled sequence 1 (5Ј-AAGAGAAATCGAAACCGAAAA-3Ј), and scrambled sequence 2 (5Ј-AAGAACCCAATTAAGCGCAAG-3Ј) were used. Sense and antisense oligonucleotides were provided by the Johns Hopkins University DNA Analysis Facility or purchased from Integrated DNA Technologies (Coralville, IA). For construction of the siRNA, a transcription-based kit from Ambion (Austin, TX) was used (Silencer siRNA construction kit). Human lung EC were then transfected with siRNA using siPORTamine as the transfection reagent (Ambion) according to the protocol provided by Ambion. Cells ‫ف(‬ 40% confluent) were serum-starved for 1 h followed by incubation with 3 M (1.5 M of each siRNA) of target siRNA (or scramble siRNA or no siRNA) for 6 h in serum-free media. The serum-containing medium was then added (10% serum final concentration) for 42 h before biochemical experiments and/or functional assays were conducted.
Determination of Serine/Threonine Phosphorylation of the S1P 3 Receptor
Solubilized proteins in IP buffer (see above) were immunoprecipitated with mouse anti-S1P 3 receptor antibody followed by SDS-PAGE in 4-15% polyacrylamide gels and transfer onto Immobilon membranes ᭤ Figure 4 . Determination of the effects of silencing mOP-R, S1P 1 receptor, or S1P 3 receptor on MNTX-induced protection from human EC barrier disruption. (A ) Immunoblot analysis of siRNA-treated or untreated human EC. Cellular lysates from untransfected (control, no siRNA), scramble siRNA (siRNA that does not target any known human mRNA), mOP-R siRNA, S1P 1 siRNA or S1P 3 siRNA-transfection were analyzed using immunoblotting with anti-mu opioid receptor antibody (a ), anti-S1P 1 antibody (b ), anti-S1P 3 antibody (c ), or anti-actin antibody (d ) as described in MATERIALS AND METHODS. Experiments were performed in triplicate each with similar results. Representative data is shown. (B ) Bar graph demonstrates the effects of silencing mOP-R, S1P 1 receptor, or S1P 3 receptor on MNTX-induced (1 h pretreatment, 0.1 M) protection from thrombin-mediated (1 U/ml) EC barrier disruption. The bar graph represents the percent maximal thrombin-induced TER response (y axis, at least n ϭ 3 for each condition). (C ) Bar graph demonstrates the effects of silencing mOP-R, S1P 1 receptor, or S1P 3 receptor on MNTXinduced (1 h pretreatment, 0.1 M) protection from LPS-mediated (1 g/ml) EC barrier disruption. The bar graph represents the percent maximal LPS-induced TER response (y axis, at least n ϭ 3 for each condition). (D ) Bar graph demonstrates the effects of silencing the S1P 3 receptor on S1P-induced EC barrier regulation. The bar graph represents the percent control (0 M S1P) TER response (y axis, at least n ϭ 3 for each condition).
(Millipore). After blocking nonspecific sites with 5% bovine serum albumin, the blots were incubated with either mouse anti-S1P 3 antibody, rabbit anti-phospho-serine, or rabbit anti-phospho-threonine antibody, followed by incubation with HRP-labeled goat anti-rabbit or goat antimouse IgG. Visualization of immunoreactive bands was achieved using enhanced chemiluminescence (Amersham Biosciences).
Measurement of EC Electrical Resistance
EC were grown to confluence in polycarbonate wells containing evaporated gold microelectrodes, and transendothelial electrical resistance (TER) measurements were performed using an electrical cell-substrate impedance sensing system obtained from Applied Biophysics as previously described in detail (2) . TER values from each microelectrode were pooled at discrete time points and plotted versus time as the mean Ϯ SE.
Animal Preparation and Treatment
Male C57BL/6J mice (8-10 wk; Jackson Laboratories, Bar Harbor, ME) were anesthetized with intraperitoneal ketamine (150 mg/kg) and acetylpromazine (15 mg/kg). LPS (2.5 mg/kg) or water (control) were instilled intratracheally. Four hours later, mice received methylnaltrexone (MNTX, 10 mg/kg) or saline control intravenously via neck incision to expose the internal jugular vein. The animals were allowed to recover for 24 h after treatment before bronchoalveolar lavage (BAL) protein analysis and/or lung immunohistochemistry.
Murine Lung Immunohistochemistry
To characterize the expression of proteins in mouse lung vascular EC, lungs from control (untreated) mice were formalin fixed, 5-m paraffin sections were obtained and hydrated, and epitope retrieval was performed (DakoCytomation Target Retrieval Solution, pH 6.0; DakoCytomation, Carpinteria, CA) The sections were then histologically evaluated by either anti-mOP-R, anti-S1P 3 receptor, or anti-Factor VIII (vWF) antibody and secondary HRP-labeled polymer with DAB staining (Dako EnVision ϩ System, HRP [DAB]; DakoCytomation) followed by hematoxylin QS counterstaining (Vector Laboratories, Burlingame, CA). Negative controls for immunohistochemical analysis were done by the same method as above but without primary antibody. Immunostained sections were photographed (ϫ100) using a Leica Axioscope (Bannockburn, IL).
Determination of BAL Protein and Cytokine Concentrations
BAL was performed by an intratracheal injection of 1 cc of Hanks' balanced salt solution followed by gentle aspiration. The recovered fluid was either processed for protein concentration (BCA Protein Assay Kit; Pierce Chemical Co., Rockford, IL) or used to determine TNF-␣ and TGF-␤1 concentrations using quantitative sandwich enzyme immunoassays (R&D Systems, Minneapolis, MN) as previously described (32). 
Statistical Analysis
Student's t test was used to compare the means of data from two or more different experimental groups. Results are expressed as means Ϯ SE.
RESULTS
The Role of MNTX in Agonist-Induced EC Barrier Disruption EC barrier disruption is an essential feature of a variety of pathologies including atherosclerosis, tumor angiogenesis, and acute lung injury (2-4, 20) . We examined the effects of MNTX, a charged peripheral mOP-R antagonist, on pulmonary microvascular EC integrity using measurements of TER. Figures 1A  and 1B indicate that ligands for the mOP-R (i.e., morphine sulfate [MS] and DAMGO) induce EC barrier disruption and reductions in TER values in a dose-dependent manner, which is consistent with previous reports (15, 33, 34) . These barrierdisruptive effects are blocked by pretreatment with a physiologically relevant dose of MNTX (0.1 M) (35) . Decreasing the dose of MNTX below 0.1 M attenuates its barrier-protective effects, while increasing the dose of MNTX beyond 0.1 M did not significantly alter these responses ( Figure 1C) .
We next examined the potential barrier protective effects of MNTX on mOP-R-independent agonist-induced EC barrier disruption. Consistent with our prior reports, thrombin induces a rapid transient decrease in EC barrier function (36-38) (reflected by TER reductions) ( Figure 2A ) and LPS induces a delayed ‫ف(‬ 4 h) EC barrier-disruptive response ( Figure 2B ) (39) (40) (41) . MNTX (0.1 M) attenuated the EC barrier disruption elicited by both thrombin and LPS (Figures 2A and 2B ), but not that induced by the Ca 2ϩ ionophore, ionomycin ( Figure 2D ) (42), indicating receptor selectivity in MNTX-mediated EC barrier protection. The protective effects of MNTX are not limited to barrier-disrupting agents, as MNTX amplified the sustained EC barrier-enhancing effect of S1P ( Figure 2C ).
MNTX is a charged molecule that cannot cross the BBB (35), allowing MNTX to selectively block peripheral mOP-R activity (35) . Consistent with this notion, naloxone, which is uncharged and promotes both peripheral and CNS mOP-R antagonist (19, 43) , also blocked MS and DAMGO-induced EC barrier disruption (0.1 M), but did not display EC barrier protection against either thrombin or LPS challenge (Figure 3) . That naloxone is 10 to 30 times as potent as MNTX clinically and in isolated Immunoblot analysis of the effects of RhoA, ROCK1, and ROCK2 siRNA on S1P 3 receptor phosphorylation with LPS treatment of human pulmonary microvascular EC. EC were either untransfected (control, no siRNA) or transfected with scramble siRNA (siRNA that does not target any known human mRNA), RhoA siRNA, ROCK1 siRNA, ROCK2 siRNA, or combined ROCK1/2 siRNA, serum starved for 1 h and were either untreated (control) or treated with LPS (1 g/ml, 4 h). Cellular lysates were then obtained and immunoprecipitated with anti-S1P 3 receptor antibody as described in MATERIALS AND METHODS. The immunoprecipitated material was immunoblotted with anti-phospho-threonine (a ) or anti-S1P 3 receptor (b ) antibody. Experiments were performed in triplicate each with similar results. Representative data are shown.
tissues suggests that the differences we observed are not due to a concentration effect (44) .
The Role of S1P 3 Receptor Transactivation in Agonist-Induced EC Barrier Disruption
Considering the actions of MNTX on opiate and S1P-induced EC barrier regulation, we next examined the effects of silencing (siRNA) the expression of the mOP-R or S1P receptor subtypes involved in MNTX-regulated EC integrity (Figure 4) . Reductions in mOP-R expression had little effect on MNTX protection against thrombin-or LPS-induced EC barrier disruption, indicating mOP-R-independent effects of MNTX on specific models of EC barrier dysfunction ( Figures 4B and 4C ). We and others have previously determined that EC express both S1P 1 and S1P 3 receptors with the S1P 1 receptor coupled to Rac1-mediated signaling, while the S1P 3 receptor activates RhoA-mediated signaling (3, 5, (21) (22) (23) 26) . Our prior studies and Figure 4D reveal that silencing of S1P 1 receptor expression completely eliminates the barrier-protective effects of S1P (0.5 and 1 M) (22), whereas higher S1P concentrations (10 M and 100 M) induce barrier disruption due to S1P 3 receptor activation (45, 46) . Silencing S1P 3 expression increases basal EC barrier function by ‫ف‬ 20% (data not shown). Figures 4B and 4C demonstrates that, in contrast to the silencing of the S1P 1 receptor, reductions in S1P 3 receptor expression inhibits both thrombin-and LPS-induced barrier disruption and loss of MNTX protection against these edemagenic agonists.
We have previously shown that S1P 1 receptor transactivation is critical to diverse agonist-induced EC barrier enhancement (3, 22, 47) . We and others have shown that the S1P 3 receptor is linked to the barrier-disruptive RhoA signaling pathway (26, 29, 48) . Given the previous published reports that the S1P 3 receptor regulates barrier function (29, 49) , we hypothesized that S1P 3 receptor transactivation and RhoA signaling may participate as a potentially central mechanism involved in loss of EC barrier integrity. Figure 5 indicates that barrier-disrupting agonists (unlike the barrier-protective 1 M S1P) promote association of the RhoA-activating GEF, p115RhoGEF, with the S1P 3 receptor ( Figure 5A ) and consequent RhoA activation ( Figure 5B ), which are inhibited by pretreatment with MNTX. Further, barrierdisrupting agonists (unlike the barrier-protective 1 M S1P) induce S1P 3 receptor transactivation (threonine phosphorylation) of the S1P 3 receptor ( Figure 6A ). Both MNTX and naloxone block morphine and DAMGO-induced S1P 3 receptor transactivation. However, MNTX (but not naloxone) also blocks thrombin and LPS-induced S1P 3 receptor transactivation, suggesting mOP-R-independent effects of MNTX. Consistent with the inhibitory effects of MNTX on agonist-induced RhoA activation, treatment of EC with an inhibitor (Y-27632) of the activated RhoA target, the serine/threonine kinase, ROCK, blocked agonist-induced S1P 3 receptor transactivation ( Figure 6A ). Silencing RhoA and/or ROCK isoforms 1 and 2, like the Y-27632 compound, blocked threonine phosphorylation of the S1P 3 receptor ( Figure 6C ) as well as attenuated thrombin and LPS-induced EC barrier disruption (Figure 7) , indicating the importance of RhoA/ROCK in these events.
Role of MNTX in LPS-Induced Pulmonary Vascular Hyperpermeability In Vivo
Similar to our results in human pulmonary microvascular EC, immunohistochemical studies reveal that murine lungs express both mOP-R and S1P 3 receptor ( Figure 8A ). We next examined whether MNTX was an effective barrier-protective agent in an in vivo model of LPS-induced murine lung vascular permeability. LPS administered via an intratracheal route induces murine inflammation and increased vascular leakiness as measured by the protein concentration in BAL fluid ( Figure 8B ), as we have previously noted (50) . Intravenous injection of MNTX (10 mg/kg) alone did not affect pulmonary vascular permeability; however, intravenous injection of MNTX 4 h after LPS delivery attenuated mouse pulmonary hyperpermeability ( Figure 8B ).
As another measure of pulmonary vascular barrier disruption, we measured the BAL concentrations of two well-characterized EC barrier-disrupting cytokines, TNF-␣ and TGF-␤1 ( Figure 9 ) (51, 52). Intravenous injection of MNTX (10 mg/kg) alone did not affect the concentrations of these cytokines in murine BAL fluid. However, intravenous injection of MNTX 4 h after LPS delivery attenuated the LPS-induced increase in TNF-␣ and TGF-␤1 BAL concentrations (Figure 9 ).
DISCUSSION
The results contained in this report include several novel observations, including the finding that MNTX, a selective peripherally restricted mOP-R antagonist, provides protection against agonist-induced EC barrier disruption via both mOP-Rdependent and -independent mechanisms. In addition, our results highlight a critical role for S1P 3 receptor transactivation (evidenced by RhoA/ROCK-mediated threonine phosphorylation) as an essential regulator of agonist-induced EC barrier disruption. Interestingly, MNTX inhibits not only morphine-and DAMGO-induced S1P 3 receptor transactivation and increased vascular permeability (Figure 10 ), but also inhibits responses to thrombin and LPS. This indicates that MNTX may be a potential clinically useful therapy for high permeability states such as atherosclerosis, tumor angiogenesis, and acute lung injury. Despite numerous attempts at optimizing doses of mOP-R antagonists, Negative controls for immunohistochemical analysis, which were done by the same method as above but without primary antibody. (B ) C57BL/6J mice were anesthetized and were either given water (control) or LPS (2.5 mg/kg) intratracheally. After 4 h, mice were given intravenously injections (internal jugular vein) with saline (control) or MNTX (10 mg/kg). The treated mice were allowed to recover for 24 h, BAL fluids were obtained, and protein concentrations were determined (see MATERIALS AND METHODS).
lipid-soluble mOP antagonists (such as naloxone) easily cross the BBB (18, 19, 35) and have proven unsuitable for patients receiving opiates for pain management due to analgesia reversal and breakthrough pain. In contrast, MNTX is a quaternary derivative of the pure narcotic antagonist naltrexone (6) , with the addition of the methyl group to naltrexone at the amine in the ring forming the compound N-methylnaltrexone with greater polarity and lower lipid solubility. MNTX does not cross the BBB and thus has significant potential as a therapeutic intervention in reversing the peripheral effects of opiates in palliative care, especially for patients taking elevated doses of opiates for analgesia (7). Two recently completed double-blind clinical trials of subcutaneous MNTX (0.15 mg or 0.3 mg) in patients with advanced medical illness suffering from opiate-induced constipation demonstrated significant reversal of constipation without affecting analgesia (9) .
The observation that MNTX, but not naloxone, protects against both thrombin-and LPS-induced EC barrier disruption indicates a highly novel finding. Although several mOP-R antagonists can inhibit opioid-induced angiogenesis (10), the effect of Figure 9 . The effect of MNTX on LPS-induced pulmonary EC barrier disruptive cytokine production in vivo. C57BL/6J mice were anesthetized and were either given water (control) or LPS (2.5 mg/kg) intratracheally. After 4 h, mice were given intravenously injections (internal jugular vein) with saline (control) or MNTX (10 mg/kg). The treated mice were allowed to recover for 24 h, BAL fluids were obtained, and the concentrations of the EC barrier disruptive cytokines TNF-␣ (A ) and TGF-␤1 (B ) were determined using quantitative sandwich enzyme immunoassays (R&D Systems) (see MATERIALS AND METHODS).
ameliorating EC barrier dysfunction with diverse EC barrierdisruptive agents such as thrombin and LPS appears selective for MNTX. Thrombin induces rapid, transient EC barrier disruption through activation of protease-activated receptors with consequent Ca 2ϩ , RhoA, and Ras/MAP kinase signaling (36-38, 53, 54) . In contrast, LPS induces a delayed EC barrier-disruptive response by activating a receptor complex of TLR4, CD14, and MD2 with consequent NF-B activation and cytokine production (39-41, 55, 56) . We have previously shown that S1P 1 receptor transactivation (AKT-mediated threonine phosphorylation) is a key component in agonist-induced EC barrier enhancement (29, 47 ). In the current study, we have extended these findings to show that RhoA/ROCK-mediated transactivation (threonine phosphorylation) of the S1P 3 receptor plays an important role in agonist-induced EC barrier disruption. ROCK inhibitors have been used to treat cardiovascular disease and acute lung injury (30, 57) . Considering our novel observation that MNTX can inhibit agonist-induced RhoA/ROCK activation, MNTX could potentially be used to treat ROCK-related diseases. Previous reports have indicated that the S1P 3 receptor is also involved in epithelial barrier disruption (49) . We are currently investigating the effects of MNTX on S1P 3 receptor-mediated lung epithelial barrier disruption. Further, we are examining the mechanisms Figure 10 . Proposed model for the protective effects of MNTX on agonist-induced EC barrier disruption. We propose that agonists such as LPS, thrombin, morphine, and DAMGO bind to their cell surface receptors (1), which promotes p115 RhoGEF association with the S1P 3 receptor (2), RhoA (3) and ROCK (4) activation, and ROCK-mediated transactivation of the S1P 3 receptor (threonine phosphorylation) (5) . Activation of S1P 3 receptor induces EC barrier disruption (6) . MNTX inhibits morphine and DAMGO binding to the mOP-R and inhibits agonist-induced, RhoA and ROCK-dependent, S1P 3 receptor transactivation. These events contribute to the protection from EC barrier disruption by MNTX.
by which MNTX exerts mOP-R-independent protective effects on EC barrier disruption.
In summary, using both in vitro and in vivo models of pulmonary vascular permeability, we have demonstrated that MNTX alone does not affect basal vascular integrity but significantly attenuates receptor edemagenic agonist-induced vascular barrier disruption. These results occur through the inhibition of a highly novel RhoA/ROCK-mediated transactivation of the S1P 3 receptor and indicate that MNTX may be a potentially useful therapeutic treatment for diseases characterized by high permeability states.
